Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSPO | P30536 | 3/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23624592 | 0.87 | TSPO (0.60) | ALDH1A1TSPONR1I2ABCB11ALB | |
| SCHEMBL23624350 | 0.82 | SLC2A1 (0.59) | ALDH1A1TSPONR1I2ABCB11ALB | |
| SCHEMBL23624275 | 0.81 | TSPO (0.69) | ALDH1A1TSPONR1I2ABCB11ALB | |
| SCHEMBL10999904 | 0.79 | GABRA2 (0.60) | ALDH1A1TSPONR1I2ABCB11ALB | |
| SCHEMBL23624269 | 0.77 | TSPO (0.88) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL8150 | 0.76 | GABRA2 (0.70) | ALDH1A1TSPONR1I2ABCB11ALB | |
| SCHEMBL11069376 | 0.74 | TSPO (0.75) | ALDH1A1TSPONR1I2ABCB11ALB | |
| SCHEMBL23624289 | 0.73 | TSPO (0.65) | ALDH1A1TSPONR1I2ABCB11ALB | |
| SCHEMBL23624118 | 0.73 | SLC2A1 (0.54) | ALDH1A1TSPONR1I2ABCB11ALB | |
| SCHEMBL23624600 | 0.72 | GABRA2 (0.53) | ALDH1A1TSPONR1I2ABCB11ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206771-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206771-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PMP22, GABBR1, MECP2 | ALDH1A1 3421/4885TSPO 275/4885NR1I2 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.